112 related articles for article (PubMed ID: 19856882)
1. [HCV entry as a new therapeutic target in chronic hepatitis C].
Dabrowska MM; Panasiuk A; Flisiak R
Pol Merkur Lekarski; 2009 Aug; 27(158):140-3. PubMed ID: 19856882
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of hepatitis C].
Moradpour D; Blum HE
Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
[TBL] [Abstract][Full Text] [Related]
3. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
4. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.
Fung J; Lai CL; Hung I; Young J; Cheng C; Wong D; Yuen MF
J Infect Dis; 2008 Sep; 198(6):808-12. PubMed ID: 18657036
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally.
Rosso R; Di Biagio A; Mikulska M; Nicco E; Bernardini C; Viscoli C
J Med Virol; 2010 Jul; 82(7):1110-4. PubMed ID: 20513072
[TBL] [Abstract][Full Text] [Related]
6. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
8. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
9. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
Aghemo A; Rumi MG; Colombo M
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
Yenice N; Mehtap O; Gümrah M; Arican N
Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
[TBL] [Abstract][Full Text] [Related]
11. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
Hepatology; 2009 Jun; 49(6):2125; author reply 2125-6. PubMed ID: 19479790
[No Abstract] [Full Text] [Related]
13. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
Sterling RK; Sulkowski MS
Semin Liver Dis; 2004; 24 Suppl 2():61-8. PubMed ID: 15346248
[TBL] [Abstract][Full Text] [Related]
14. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
Zeuzem S; Nelson DR; Marcellin P
Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
[TBL] [Abstract][Full Text] [Related]
15. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
[TBL] [Abstract][Full Text] [Related]
16. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
17. Optimizing treatment regimens in hepatitis C.
Darling JM; Fried MW
Clin Liver Dis; 2006 Nov; 10(4):835-50. PubMed ID: 17164120
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis C.
Bihl F; Negro F
Minerva Med; 2009 Dec; 100(6):459-65. PubMed ID: 20010481
[TBL] [Abstract][Full Text] [Related]
19. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
Milazzo L; Caramma I; Mazzali C; Cesari M; Olivetti M; Galli M; Antinori S
J Antimicrob Chemother; 2010 Apr; 65(4):735-40. PubMed ID: 20118492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
